CD274 and small cell lung carcinoma: Unlike patients with advanced or recurrent NSCLC, whose personalized therapy is guided by a range of oncogenic driver mutations and PD-L1 levels, identifying biomarkers and therapeutic targets in SCLC continues to pose a challenge.